Elicera Therapeutics (ELIC) Q1 2025 earnings summary

Executive summary

• Operating loss for Q1 2025 was SEK -8.1 million, a wider loss compared to SEK -5.4 million in Q1 2024, mainly due to lower grant income.

• Loss for the period was SEK -8.0 million, with EPS at SEK -0.22, an improvement from SEK -0.26 in Q1 2024.

• Cash flow from operating activities improved to SEK -0.7 million from SEK -9.3 million year-over-year.

• ELC-100 received Orphan Drug Designation in the U.S. for pancreatic neuroendocrine tumors.

• First clinical results from iTANK-armed CAR T-cell therapy showed a complete response in the first patient, with no serious side effects.

Financial highlights

• Operating loss: SEK -8,069,404 (Q1 2024: -5,433,422).

• Loss for the period: SEK -8,013,462 (Q1 2024: -5,369,677).

• Cash and cash equivalents at period end: SEK 45.7 million (Q1 2024: 40.7 million).

• Cash flow from financing activities: SEK 20.0 million (Q1 2024: 20.6 million).

• New share issue and warrant exercise raised SEK 22.0 million before costs.

Outlook and guidance

• Preliminary results from the CARMA study (ELC-301) will be reported as each dosing group is completed, with updates planned for 2025 and 2026.

• Final data from the ELC-100 dose escalation trial in neuroendocrine tumors expected around mid-2025.

• Continued focus on advancing clinical programs and leveraging strong capital position.